Golparian D, Jacobsson S, Ohnishi M, Unemo M
Microbiol Resour Announc 12 (3) e0113022 [2023-03-16; online 2023-02-28]
Zoliflodacin is a promising novel antimicrobial in clinical development for treatment of gonorrhea; currently, it is in a global phase 3 randomized controlled clinical trial. High activity against global Neisseria gonorrhoeae strains has been shown. We present the complete reference genome of the zoliflodacin-resistant strain H035, which was identified in Japan in 2000.